From the ann:"Significant opportunity for Prima to tap into...

From the ann:
"Significant opportunity for Prima to tap into US$517 million Middle East cancer therapy market."

If Cvac were to capture only 1% of that entire market US$5 mill p.a. in immediate revenue.

Another way to look at it, Provenge is sold in the US for about $95,000 per patient.

Assume DHCC treats a mere 50 patients with Cvac per annum on the same cost basis, thats near enough US$5 mill again.

Apply a very conservative (for Biomeds)P/E of 16 times earnings and divide by (roughly) 1 bill shares on issue.

On those very conservative estimates, Dubai alone adds 8 cents per share in value.